Sam Meiklejohn

Partner

Gateley Legal logo

Sam Meiklejohn

Expertise

Sam focuses his practice on equity capital markets, public companies and corporate governance. He advises corporates, investment banks, brokers and major shareholders on a broad spectrum of capital markets matters including primary and secondary securities offerings listed on both UK and international stock exchanges. His experience covers a wide range of sectors, including life sciences, technology, and biotech. He also has significant cross-border transactional experience, including transatlantic, pan-European and across the MENA region. Sam also advises private companies, founders, and venture capital firms on private fundraises from seed capital through to series fundraising. Sam works with start-ups and founders on all aspects of corporate growth strategy, scale-up and university spin-outs.

How do you help clients?

I help my clients in all aspects of their life (or soon-to-be life) on the public markets, whether that be advising on their IPO, raising further capital or on the day-to-day issues that arise by virtue of being a listed company. I equally enjoy working with brokers, banks and other advisors to help both private and public companies achieve their strategic goals. I also work with start-ups, founders and venture capital firms on raising capital and providing strategic growth advice.

Experience

  1. Acting for Inspired plc on its £183.6m recommended takeover by US private equity firm, HGGC, LLC.
  2. Acting for Inspired plc on its £26.66m fundraising by way of: (i) a placing of new ordinary shares; (ii) an issue of convertible loan notes; and (iii) a retail offer of new ordinary shares.
  3. Acting for Scancell Holdings plc on multiple equity raises including a placing, subscription and open offer.
  4. Acting for Redx Pharma plc on multiple equity raises including a placing and subscription.
  5. Acting for AdvancedAdvT Limited on its admission to trading on AIM.
  6. Acting for Renalytix plc on its IPO on AIM, subsequent dual-listing on the Nasdaq in the US and multiple secondary fundraises.
  7. Acting for multiple UK-incorporated biotechs on their US IPOs, secondary fundraisings, UK statutory obligations and other general corporate governance matters.